すていく

× {{flash.message}} Toggle navigation Toggle navigation 日本語 | English 新規登録ログイン 齋田 良知 Yoshitomo Saita 更新日: 03/28 ホーム研究分野受賞論文MISC共同研究・競争的資金等の研究課題 論文 国際誌 2022年11月22日 Study protocol for a randomised placebo controlled trial of platelet-rich plasma injection to prevent post-traumatic knee osteoarthritis after anterior cruciate ligament reconstruction. BMJ open Yasumasa Momoi Yoshitomo Saita Masashi Nagao Yohei Kobayashi Ryosuke Nakajima Sayuri Uchino Takanori Wakayama Hirofumi Nishio Shin Fukusato Suguru Wakana Jun Tomura Keiji Kobayashi Keiichi Yoshida Haruka Kaneko Mitsuaki Kubota Muneaki Ishijima … 全て表示 折りたたむ 巻 12 号 11 開始ページ e061484 終了ページ 記述言語 英語 掲載種別 研究論文（学術雑誌） DOI 10.1136/bmjopen-2022-061484 INTRODUCTION: The elevated cytokine levels in patients suffering from anterior cruciate ligament (ACL) rupture may lead to acute post-traumatic arthritis (APTA) and post-traumatic osteoarthritis (PTOA). Due to its chondrogenerative and anti-inflammatory effect, platelet-rich plasma (PRP) therapy is expected to show a positive outcome in APTA and PTOA. The proposed trial aims to quantitatively measure the efficacy of PRP injection in arresting post-traumatic cartilage degeneration among patients after ACL reconstruction. METHODS AND ANALYSIS: This will be a single-blind, randomised, prospective, controlled clinical trial designed following the Consolidated Standards of Reporting Trials guidelines. After ACL reconstruction, 80 patients will be randomised to receive either leucocyte-poor PRP injection after joint aspiration or a placebo control group receiving only joint aspiration. Participants (age 20-49 years) will be those who have undergone ACL reconstruction within the past 2 weeks with a body mass index<35 and Kellgren Lawrence osteoarthritis grade<2. The primary outcome will include MRI-T2 values of knee cartilage at 6 months. The secondary outcomes will include pain assessment by Visual Analogue Scale, Knee injury and Osteoarthritis Outcome Score, blood and urine test, physical findings, measurements for muscle strength and joint stability. ETHICS AND DISSEMINATION: The study was approved by The Independent Ethics Committee for Clinical Trials of the Japanese Association for the Promotion of State-of-the-Art Medicine. Results of the trial and each of the outcomes will be shared via conferences and publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: jRCTb030200391. リンク情報 DOIhttps://doi.org/10.1136/bmjopen-2022-061484PubMedhttps://www.ncbi.nlm.nih.gov/pubmed/36414304PubMed Centralhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685167 ID情報 DOI : 10.1136/bmjopen-2022-061484PubMed ID : 36414304PubMed Central 記事ID : PMC9685167 エクスポート BibTeX RIS 論文リストへ メニュー マイポータル 研究ブログ資料公開 共著者の一覧 まだ共著者が1人も登録されていません。 {{coauthor.Related.name_str}} {{coauthor.Related.last_modified}} 更新 limit"> もっとみる 2017 researchmap 利用規約